Study of INCA033989 for myeloproliferative neoplasms
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed CALR gene mutation (tested by a local lab).
- You must have myelofibrosis (MF) or essential thrombocythemia (ET).
- You need to be willing to have bone marrow biopsies and blood draws regularly.
- You must not have had any major bleeding or blood clot in the last 3 months.
- You cannot have had a stem cell transplant or plan to have one.
- You must not have had other cancer treatments (except ruxolitinib) in the last 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
This trial tests a combination of two targeted drugs, ivosidenib and ruxolitinib, for people with advanced myeloproliferative neoplasms (MPNs) that have an IDH1 gene mutation. The goal is to see if this treatment can help control the disease.
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial is testing an experimental drug called DMR-001 for people with blood cancers like ET or myelofibrosis who have a specific genetic change known as a CALR mutation. The goal is to see if the drug is safe, tolerable, and helps treat the disease.
Hear when a new Myeloproliferative Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.